AU2001262027A1 - Use of substances that act as cascade inhibitors of the Raf/MEK/ERK signal cascade, for producing a medicament to treat DNA and RNA viruses - Google Patents

Use of substances that act as cascade inhibitors of the Raf/MEK/ERK signal cascade, for producing a medicament to treat DNA and RNA viruses

Info

Publication number
AU2001262027A1
AU2001262027A1 AU2001262027A AU2001262027A AU2001262027A1 AU 2001262027 A1 AU2001262027 A1 AU 2001262027A1 AU 2001262027 A AU2001262027 A AU 2001262027A AU 2001262027 A AU2001262027 A AU 2001262027A AU 2001262027 A1 AU2001262027 A1 AU 2001262027A1
Authority
AU
Australia
Prior art keywords
cascade
raf
mek
medicament
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001262027A
Other versions
AU2001262027B2 (en
AU2001262027B8 (en
Inventor
Stephan Ludwig
Stephan Pleschka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atriva Therapeutics GmbH
Original Assignee
Atriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10017480A external-priority patent/DE10017480A1/en
Application filed by Atriva Therapeutics GmbH filed Critical Atriva Therapeutics GmbH
Publication of AU2001262027A1 publication Critical patent/AU2001262027A1/en
Publication of AU2001262027B2 publication Critical patent/AU2001262027B2/en
Application granted granted Critical
Publication of AU2001262027B8 publication Critical patent/AU2001262027B8/en
Assigned to ACTIVAERO GMBH reassignment ACTIVAERO GMBH Request for Assignment Assignors: MEDINNOVA GESELLSCHAFT FUR MEDIZINISCHE INNOVATIONEN AUS AKADEMISCHER FORSCHUNG MBH
Assigned to ATRIVA THERAPEUTICS GMBH reassignment ATRIVA THERAPEUTICS GMBH Request for Assignment Assignors: ACTIVAERO GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

AU2001262027A 2000-04-07 2001-04-05 Use of substances that act as cascade inhibitors of the Raf/MEK/ERK signal cascade, for producing a medicament to treat DNA and RNA viruses Expired AU2001262027B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10017480.9 2000-04-07
DE10017480A DE10017480A1 (en) 2000-04-07 2000-04-07 Use of substances that act as MEK inhibitors for the manufacture of a medicament against DNA and RNA viruses
PCT/DE2001/001292 WO2001076570A2 (en) 2000-04-07 2001-04-05 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses

Publications (3)

Publication Number Publication Date
AU2001262027A1 true AU2001262027A1 (en) 2002-01-10
AU2001262027B2 AU2001262027B2 (en) 2006-03-09
AU2001262027B8 AU2001262027B8 (en) 2006-04-06

Family

ID=7638027

Family Applications (2)

Application Number Title Priority Date Filing Date
AU6202701A Pending AU6202701A (en) 2000-04-07 2001-04-05 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses
AU2001262027A Expired AU2001262027B8 (en) 2000-04-07 2001-04-05 Use of substances that act as cascade inhibitors of the Raf/MEK/ERK signal cascade, for producing a medicament to treat DNA and RNA viruses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU6202701A Pending AU6202701A (en) 2000-04-07 2001-04-05 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses

Country Status (10)

Country Link
US (3) US20030060469A1 (en)
EP (1) EP1274421B1 (en)
JP (1) JP2004505891A (en)
CN (1) CN1268329C (en)
AT (1) ATE334670T1 (en)
AU (2) AU6202701A (en)
CA (1) CA2405307C (en)
DE (2) DE10017480A1 (en)
ES (1) ES2269404T3 (en)
WO (1) WO2001076570A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149462A0 (en) * 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE10138912A1 (en) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Use of active substances for the prophylaxis and / or therapy of viral diseases as well as test system for finding such active substances
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
CA2522333A1 (en) * 2003-04-14 2004-10-21 Novartis Ag Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases
WO2005007616A1 (en) * 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
RU2352558C2 (en) * 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Polymorphic form of n-[(r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
CN103221043B (en) 2010-08-05 2016-04-06 卡斯西部储备大学 Be used for the treatment of neuron and connect stunted ERK inhibitor
EP2714037B1 (en) 2011-05-25 2016-07-13 Université Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
AU2013328824B2 (en) 2012-10-08 2018-04-05 Atriva Therapeutics Gmbh MEK inhibitors in the treatment of virus diseases
PT3697405T (en) * 2017-10-17 2021-08-27 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
EP3708684B1 (en) 2019-03-15 2022-03-02 Primetals Technologies Austria GmbH Method for direct reduction in a fluidised bed
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
LU101183B1 (en) 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
AU2020338695A1 (en) 2019-08-27 2022-03-24 Atriva Therapeutics Gmbh Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
AU2020362953A1 (en) 2019-10-08 2022-04-14 Atriva Therapeutics Gmbh MEK inhibitors for the treatment of hantavirus infections
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
BR9810385A (en) * 1997-07-01 2000-09-05 Warner Lambert Co Derivatives of benzoic acid 2- (4-bromine or 4-iodine phenylamino) and their use as mek inhibitors
AU757046B2 (en) * 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
CN101317589A (en) * 1998-07-28 2008-12-10 艾科斯迈特技术公司 Synergistic and residual pesticidal compositions containing plant essential oils.
AU2203800A (en) * 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
DE69928286T2 (en) * 1999-01-13 2006-07-13 Warner-Lambert Co. Llc BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS
JP2002534515A (en) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 1-heterocyclic-substituted diarylamines
JP2001055376A (en) * 1999-01-13 2001-02-27 Warner Lambert Co Diaryl amine
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression

Similar Documents

Publication Publication Date Title
AU2001262027A1 (en) Use of substances that act as cascade inhibitors of the Raf/MEK/ERK signal cascade, for producing a medicament to treat DNA and RNA viruses
AU2002359436A1 (en) Dna amplification and sequencing using dna molecules generated by random fragmentation
AU5210798A (en) Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
AU2002252183A1 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
EP1414842A4 (en) Antisense modulation of acyl coa cholesterol acyltransferase-2 expression
WO1996021731A3 (en) Stabilized external guide sequences
MXPA03004794A (en) New mandelic acid derivatives and their use as throbin inhibitors.
WO2001076570A3 (en) Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
WO2002037927A3 (en) Compounds and methods for promoting smoking cessation
AU2001241674A1 (en) Variant galactose oxidase, nucleic acid encoding same, and methods of using same
AU2001247414A1 (en) Oligonucleotide analogues, methods of synthesis and methods of use
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AU2001231706A1 (en) Catalyst for decomposing N2O, its use and method for the production thereof
AU2002211465A1 (en) Alteration of plant nitrate and oxalic acid concentration
MX282119B (en) Process for epoxidation and catalyst to be used therein.
WO2002030941A3 (en) Topoisomerase inhibitors
AU2003255612A1 (en) Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
AU2003274905A1 (en) Recombinant double-stranded rna phage, and use of the same
AU2003294652A1 (en) Method and reactor for the amplification of dna
AU2002219140A1 (en) Modulating gene expression in insects by using double-stranded rna (dsrna)
AU2001287534A1 (en) Use of flupirtine to treat tinnitus
AU2001244834A1 (en) Novel strain for decomposing tmah, and method of wastewater treatment using the same